QuidelOrtho Corporation

Equities

QDEL

US2197981051

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
42.5 ^USD	+0.66%		+7.21%	-42.33%

May. 02	QuidelOrtho Corporation Announces CEO Changes	CI
May. 02	QuidelOrtho Corporation Appoints Brian J. Blaser as President and to the Board	CI

QuidelOrtho Corporation announces an Equity Buyback for $300 million worth of its shares.

August 17, 2022 at 04:56 pm EDT

QuidelOrtho Corporation (NasdaqGS:QDEL) announces a share repurchase program. Under the program, the company will repurchase up to $300 million worth of its common stock The repurchase program will expire on August 17, 2024.

Latest news about QuidelOrtho Corporation

QuidelOrtho Corporation Announces CEO Changes	May. 02	CI
QuidelOrtho Corporation Appoints Brian J. Blaser as President and to the Board	May. 02	CI
QuidelOrtho Shares Fall on Decision to Withdraw FDA 510(k) Submission for Savanna RVP4+ Assay	Apr. 02	MT
QuidelOrtho Gets US FDA Clearance For QuickVue COVID-19 Test	Apr. 02	MT
QuidelOrtho Corporation Receives FDA 510(K) Clearance for its QuickVue COVID-19 Test	Apr. 02	CI
QuidelOrtho Receives Canada's Approval for Triage PLGF Test to Detect Pregnancy Complications	Mar. 06	MT
Transcript : QuidelOrtho Corporation Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-05-2024 04:00 PM	Mar. 05
Sector Update: Health Care Stocks Mixed Late Afternoon	Mar. 04	MT
Sector Update: Health Care	Mar. 04	MT
QuidelOrtho Shares Decline Following UBS Downgrade	Mar. 04	MT
UBS Downgrades QuidelOrtho to Sell From Neutral, Adjusts Price Target to $42 From $70	Mar. 04	MT
Sector Update: Health Care Stocks Mixed in Late Afternoon	Feb. 21	MT
Sector Update: Health Care	Feb. 21	MT
QuidelOrtho Terminates CEO Douglas Bryant, Postpones Investor Day	Feb. 21	MT
QuidelOrtho Corporation Announces CEO Changes	Feb. 21	CI
QuidelOrtho Corporation Announces Changes in Executive Leadership, Effective from February 21, 2024	Feb. 21	CI
Sector Update: Health Care Stocks Gain Late Afternoon	Feb. 14	MT
Sector Update: Health Care Stocks Rise in Afternoon Trading	Feb. 14	MT
Top Midday Decliners	Feb. 14	MT
QuidelOrtho Shares Slump After Analysts Downgrade Stock Following Lower Q4 Results	Feb. 14	MT
William Blair Downgrades QuidelOrtho to Market Perform From Outperform	Feb. 14	MT
Citigroup Adjusts Price Target on QuidelOrtho to $50 From $72, Maintains Neutral Rating	Feb. 14	MT
Craig-Hallum Downgrades QuidelOrtho to Hold From Buy, Adjusts Price Target to $50 From $158	Feb. 14	MT
Raymond James Downgrades QuidelOrtho to Outperform From Strong Buy, Cuts Price Target to $76 From $100	Feb. 14	MT
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	Feb. 14	MT

Chart QuidelOrtho Corporation

Duration

Period

More charts

Company Profile

QuidelOrtho Corporation is engaged in vitro diagnostics, developing and manufacturing intelligent solutions. The Company sells its products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care (POC) settings, blood banks and donor centers, as well as for individual, non-professional, over the counter (OTC) use. The Company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Connect, Ortho Plus, Ortho Vision, QuickVue, Quidel, QuidelOrtho, QVue, Savanna, Sofia, Solana, Thyretain, Triage, Virena, Vitros among others. It provides support for its customers across more than 130 countries and territories.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-07 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for QuidelOrtho Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

42.5 USD

Average target price

54.4 USD

Spread / Average Target

+28.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Diagnostic & Testing Equipment

	1st Jan change	Capi.
QUIDELORTHO CORPORATION	-42.33%	2.84B
SARTORIUS AG	-14.68%	18.88B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+17.00%	1.85B
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-0.51%	1.66B
BIOTAGE AB	+27.15%	1.26B
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-13.90%	989M
CONTEC MEDICAL SYSTEMS CO.,LTD	-21.76%	896M
REVENIO GROUP OYJ	-2.72%	757M
VAREX IMAGING CORPORATION	-23.95%	633M
CELLAVISION AB	+6.84%	500M

Medical Diagnostic & Testing Equipment